Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent
March 26, 2015 at 08:02 AM EDT
Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the dosing of patients in a ...